- Home
- TIL vs ALGS Comparison
TIL vs ALGS Comparison
Compare TIL & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TIL | ALGS |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 62.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TIL | ALGS |
|---|---|---|
| Price | $7.13 | $9.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $125.00 | $46.67 |
| AVG Volume (30 Days) | ★ 251.8K | 71.3K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.67 | $3.76 |
| 52 Week High | $42.79 | $37.12 |
Technical Indicators
Market Signals| Indicator | TIL | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 30.97 | 45.21 |
| Support Level | $5.67 | $8.25 |
| Resistance Level | $7.42 | $10.49 |
| Average True Range (ATR) | 0.73 | 0.91 |
| MACD | -0.33 | -0.14 |
| Stochastic Oscillator | 19.65 | 24.62 |
Price Performance
Historical ComparisonAbout TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.